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Abstract
Background: Multicentric Castleman’s disease (MCD) is a pre-malignancy that presents with lymphadenopathy and
features of systemic inflammation. Human immunodeficiency virus (HIV)-associated MCD is associated with human
herpesvirus-8 (HHV-8) infection. If untreated MCD has a relapsing and remitting course that is eventually fatal.
Case presentation: A 67-year-old man had six hospital admissions over 20 months characterised by fever, urinary
frequency and CRP >100 mg/L. The final admission was complicated by hypotension requiring intensive care unit
admission and ionotropic support. His history included HIV and Hepatitis B virus (HBV) co-infection on suppressive
therapy. Each presentation was managed as presumed urosepsis with use of empirical antibiotics, however numerous
blood and urine cultures failed to identify a pathogen. A bone-marrow aspirate and trephine found no evidence
of haematological malignancy. A positron emission tomography scan found active lymph nodes, one of which
was biopsied and found to contain the plasma-cell variant of Castleman’s disease. Ultimately the cause for the
recurrent presentations was attributed to progressive MCD. The patient received rituximab monotherapy and has
had no further related admissions.
Conclusions: MCD should be considered in patients with chronic HIV infection presenting with recurrent sepsis-like
episodes and/or vasodilatory shock, particularly if no pathogen is identified or lymphadenopathy is evident.
Keywords: Multicentric Castleman’s disease, MCD, HHV-8, Human herpes virus-8, HIV, Fevers, Shock, Rituximab,
Systemic inflammatory response syndrome, SIRS
Background
Castleman’s disease is a rare, pre-malignant, polyclonal
lymphoproliferative disorder of unknown aetiology [1].
Estimates suggest a prevalence of 2.4 per million [2]
with a male and Caucasian preponderance and a me-
dian age of 55 years [2]. Unicentric Castleman’s disease
typically involves a single lymph node that may be
cured by excision. In contrast, multicentric Castleman’s
disease (MCD) is an aggressive condition marked by
generalised lymphadenopathy, extra-nodal disease, and
clinical features of a systemic inflammatory response [2].
Early in the human immunodeficiency virus (HIV) pan-
demic clinicians noted an association between Kaposi’s
sarcoma and MCD. It was subsequently recognised that
both conditions shared an association with human herpes
virus-8 (HHV-8) [3]. A recent study of MCD cases from
two centres found 15 % were HIV-associated and 17 %
HHV-8-associated, with nearly all cases of HIV-associated
MCD expressing histologically detectable HHV-8 antigen
[4]. The proposed pathogenesis of HIV-associated MCD is
that immunodeficiency promotes viral replication of
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The majority of HIV-associated MCD are plasma
cell-variant or mixed plasma-cell-hyaline variant [3].
Coexistence of Kaposi’s sarcoma has been found in
40–75 % of cases [3, 5, 6] and an association between
MCD and non-Hodgkin’s lymphoma and primary effusion
lymphoma has been recognised [3]. In the absence of
treatment, MCD has a relapsing and remitting course that
is eventually fatal [4, 7].
MCD commonly presents with a syndrome of fevers,
fatigue, night sweats, weight loss, lymphadenopathy and
hepatosplenomegaly. Laboratory abnormalities include
raised serum C-reactive protein (CRP) and interleukin
(IL)-6, cytopenias and polyclonal hypergammaglobuli-
neamia. Computed tomography (CT) imaging typically
shows diffuse adenopathy and splenomegaly. The diag-
nosis is confirmed by histological examination of lymph
node tissue.
The pathogenesis of MCD remains poorly understood,
however infection of immunoblasts with HHV-8 appears
to trigger an intense immune response and marked pro-
duction of host-derived IL-6. HHV-8 also encodes an
early homologue of IL-6 (vIL-6) [8] and this plays a
pathogenic role by stimulating B-cell proliferation and
oncogenesis [9]. Elevated circulating IL-6 derived from
both host and HHV-8 is thought to contribute to the
manifestations of a systemic inflammatory response
[10, 11] and related laboratory findings [3]. Kaposi sar-
coma herpesvirus-inflammatory cytokine syndrome (KICS)
has recently been described which can occur in the setting
of HHV-8 and elevated IL-6 in the absence of the histo-
logical finding of MCD [4, 12, 13].
Here we report a case that aims to illustrate the chal-
lenges surrounding the diagnosis of MCD due to non-
specific symptoms that relapse and remit and may resemble
other conditions, and a lack of standardised diagnostic
criteria. Additionally, current treatment strategies and ra-
tionale are summarised. The patient had a background of
chronic, well-controlled HIV-infection and had multiple
hospital presentations characterised by fever and urinary
frequency that mimicked urosepsis. No pathogenic organ-
isms were isolated from multiple urine and blood cultures.
The last episode was characterised by systemic inflamma-
tory response syndrome (SIRS) [14] and vasodilatory shock,
requiring intensive care unit (ICU) admission and ionotro-
pic support. Following diagnosis and treatment for his
MCD his fevers abated promptly with no further episodes
of fevers or shock.
Case presentation
A 67 year old man of Mediterranean descent presented
with vomiting and diarrhoea. His past medical history
included advanced HIV-1 infection diagnosed 4 years
prior and hepatitis B virus (HBV) co-infection on com-
bination antiretroviral therapy (ART) targeting both
viruses, gastro-oesophageal reflux disease (GORD), vita-
min D deficiency and depression. Medications at presen-
tation were: atazanavir 400 mg, zidovudine 250 mg,
etravirine 200 mg BD, raltegravir 400 mg BD, ranitidine
300 mg, fluconazole 200 mg, sertraline 50 mg and chole-
calciferol 25 μg.
On examination, he had a low grade fever to 37.7 °C
and a normal cardiopulmonary examination. He had
palpable discrete cervical and axillary lymphadenopathy.
There was generalised abdominal tenderness and hepa-
tosplenomegaly without ascites.
Laboratory investigations on initial presentation are
shown in Table 1. The most salient finding was an ele-
vated CRP of 132 mg/L (Fig. 1, Admission #1). The CD4
T-cell count was 0.34 x 109 cells/L and the HIV-1 RNA
plasma viral load was undetectable to a level of 37 copies/
mL. Five blood cultures and two urine cultures returned
no growth. Stool microscopy, culture and serum cyto-
megalovirus (CMV) DNA quantitation were negative.
The palpable lymphadenopathy and splenomegaly were
further investigated by a positron emission tomography
(PET) scan that demonstrated increased metabolism in
the spleen and mild-to-moderately increased metabolism
in the bone marrow. Metabolism was also increased in
lymph nodes above and below the diaphragm, many of
which were not enlarged. These findings were reported as
being most consistent with a well-differentiated lympho-
proliferative disease process. The patient had attended an
outpatient CT of the chest, abdomen and pelvis eight days
prior to admission which found mild splenomegaly at
13.5 cm but no evidence of pathologic lymphadenopathy.
A bone marrow aspirate and trephine was performed
to investigate for haematological malignancy or occult
infection such as Leishmania. The bone marrow was
hypercellular with moderate tri-lineage dysplasia, re-
ported as consistent with HIV infection. There was no
evidence of bone marrow involvement by a lymphopro-
liferative neoplasm. The patient’s symptoms improved
with supportive intravenous fluid and he was discharged
after ten days with an outpatient Haematology appoint-
ment and a plan to further investigate for an underlying
lymphoproliferative disease, however he did not attend
this appointment.
Over the following 4 months, between December 2013
and March 2014, the patient had three hospital admis-
sions each characterised by fevers >38 °C, generalised
abdominal pain, urinary frequency and a CRP >100 mg/
L (Fig. 1). Each of these admissions was managed as pre-
sumed urosepsis on the basis of fever, abdominal pain
and urinary frequency and involved treatment with em-
pirical intravenous antibiotics. However, numerous
blood and urine cultures taken on each occasion failed
to isolate a pathogen. Admission #2 was seven days long.
During this time the patient had two sets of blood
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cultures and one urine culture which showed no growth
prior to treatment with IV ceftriaxone and gentamicin.
A CT of the renal tract showed left perinephric strand-
ing with no features of obstruction, reported as possibly
consistent with a recent calculus. Admission #3 (twelve
days duration) included four sets of negative blood cul-
tures and two negative urine cultures. All were taken
prior to IV ciprofloxacin therapy. During this admission
the patient had a systolic blood pressure of 78 mmHg
requiring IV fluids in an ICU. During admission #4
(eleven days duration) the patient was hypotensive on
admission (95/40 mmHg), but responded to IV fluids.
He had four negative blood cultures and two negative
urine cultures prior to treatment with IV ceftriaxone and
gentamicin. He was commenced on tamsulosin, prophy-
lactic sulfamethoxazole-trimethoprim 400/80 mg daily
and referred for outpatient cystoscopy for further inves-
tigation of recurrent urosepsis. In January 2015 the pa-
tient re-presented to the Emergency Department with
urinary frequency and loin pain (Fig. 1, Admission #5).
He was febrile (38.1 °C) with flank tenderness. He was
again admitted with presumptive urosepsis and com-
menced on IV ceftriaxone and gentamicin. A CT of the
renal tract was performed and found a left hydroureter
and abdominal lymphadenopathy. The patient remained
febrile, however antibiotics were ceased on Day 3 after
urine and blood cultures found no growth and clinical
suspicion for an underlying neoplastic process was high.
A PET scan was performed, this time demonstrating
multiple active lymph nodes above and below diaphragm
considered suggestive of a slowly progressing well-
differentiated lymphoma (Fig. 2e). A CT chest, abdomen






White cell count 3.6 × 109/L 5.3 × 109/L 4.0–10.0 x109/L
Haemoglobin 134 g/L 126 g/L 130–170 g/L
Platelets 135 × 109/L 91 × 109/L 150–400 x109/L
Packed cell volume 0.40 L/L 0.37 L/L 0.40–0.50 L/L
Mean corpuscular volume 107.0 fL 111.0 fL 80–100 fL
Red cell count 3.77 × 1012/L 3.37 × 1012/L 4.50–5.50 x1012.L
Mean corpuscular haemoglobin 35.5 pg 37.4 pg 27.0–32.0 pg
Mean corpuscular haemoglobin concentration 332 g/L 338 g/L 315–355 g/L
Red cell distribution width 13.5 % 14.7 % 11.6–14.0 %
Neutrophils 2.7 × 109/L 3.2 × 109/L 2.0–7.0 x109/L
Lymphocytes 0.5 × 109/L 1.0 × 109/L 1.0–3.0 x109/L
Monocytes 0.2 × 109/L 0.9 × 109/L 0.2–1.0 x109/L
Eosinophils 0.1 × 109/L 0.1 × 109/L 0.0–0.5 x109/L
Basophils 0.0 × 109/L 0.0 × 109/L 0.0–0.1 x109/L
Sodium 137 mmol/L 135 mmol/L 135–145 mmol/L
Potassium 4.0 mmol/L 4.6 mmol/L 3.5–5.0 mmol/L
Chloride 99 mmol/L 97 mmol/L 97–109 mmol/L
Bicarbonate 22 mmol/L 23 mmol/L 24–32 mmol/L
Urea 7.6 mmol/L 8.4 mmol/L 3.0–8.0 mmol/L
Creatinine 98 μmol/L 103 μmol/L 70–110 μmol/L
Estimated glomerular filtration rate 69 mL/min/1.73 m2 64 mL/min/1.73 m2 ≥60 mL/min/1.73 m2
Bilirubin 9 μmol/L 21 μmol/L ≤21 μmol/L
Albumin 39 g/L 38 g/L 38–48 g/L
Protein 70 g/L 73 g/L 62–80 g/L
Lactate dehydrogenase 182U/L ND <220U/L
Alkaline phosphatise 79 U/L 75 U/L 30–130 U/L
Gamma- glutamyl transpeptidase 12 U/L 14 U/L ≤60 U/L
Aspartate aminotransferase 18 U/L 16 U/L 5–55 U/L
Alanine aminotransferase 16 U/L 16 U/L 5–55 U/L
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and pelvis showed splenomegaly (Fig. 2a, c), right supra-
clavicular adenopathy, peripancreatic adenopathy and
mild retrocaval adenopathy. The patient underwent an
ultrasound guided core biopsy of the right supraclavicu-
lar node. The patient defervesced and he was discharged
on Day 12 with plans for outpatient follow-up.
The histopathology of his excised lymph node found
preserved architecture with expanded interfollicular areas
including numerous mature, polyclonal plasma cells. Im-
munohistochemistry for HHV-8 showed occasional posi-
tive staining cells in the mantle zone (Fig. 2f–h). These
findings were reported as diagnostic of the plasma cell
variant of Castleman’s disease. A plasma IL-6 level was el-
evated at 29.6 pg/mL (reference range <6.0 pg/mL) and
HHV-8 DNA was detected in the serum in a qualitative
assay as quantitation was unavailable.
The patient presented to the Emergency Department
again 4 weeks later, prior to his outpatient follow-up,
with a three-day history of dysuria, frequency and
flank pain (Fig. 1, Admission #6). The patient was
febrile to 38.6 °C, hypotensive (98/66 mmHg) and
tachypnoeic, meeting the criteria for SIRS [14]. His
abdomen was distended with palpable hepatospleno-
megaly. Laboratory values are shown in Table 1. A CT
of the renal tract was performed and reported no iden-
tifiable calculus however there was bilateral peri-
nephric and peri-ureteric fat stranding with mild
dilatation of both ureters. IV vancomycin and genta-
micin were commenced to cover for urosepsis. The
patient remained hypotensive and unstable despite
fluid resuscitation, necessitating transfer to an ICU.
The patient was commenced on single strength nor-
adrenaline (SSNAdr) initially requiring 32 mL/hr to
maintain a mean arterial pressure (MAP) of >65 mmHg.
He received 1 L of 4 % albumin. This reduced his
SSNAdr requirements to 12 mL/hr and increased his
urine output from 0 to 15 mL/hr to 60 mL/hr.
A renal DTPA-scan was performed and found normal
renal perfusion but minimal renal function, a result
likely confounded by use of noradrenaline. An intraven-
ous pyelogram again made mention of bilateral peri-
nephric stranding and the absence of hydronephrosis.
An abdominal ultrasound was performed to exclude a
biliary cause of sepsis. No cause for the patient’s clinical
deterioration could be identified. A total of three sets
of blood cultures and two urine cultures were obtained.
No growth was reported in any of these specimens.
While there was initial uncertainty surrounding attrib-
uting the patients fevers, flank pain and hypotension to
the recently diagnosed haematological disorder, ultim-
ately the cause for the patient’s symptoms was consid-
ered to be progressive MCD as previously described
[15]. His SSNAdr infusion was ceased on Day 3 by
which time the patient had been afebrile for 48 h. The
patient was transferred to the ward on Day 6 of admis-
sion and was discharged on Day 12 with outpatient
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Fig. 1 Summary of hospital admissions spanning 20 months. Data from six hospital admissions between October 2013 and May 2015 are shown.
C-reactive protein is shown on the left y-axis (black) with upper limit of normal 5 mg/L (black dashed line). Haemoglobin is shown on the right
y-axis (gray) with lower limit of normal 130 g/L (gray dashed line). BC blood culture; UC urine culture
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The patient was subsequently treated with rituximab
monotherapy infusions at 375 mg/m2 for four doses
weekly which was well tolerated. A progress CT found sig-
nificant reduction in the size and number of the promin-
ent lymph nodes and a reduction in splenomegaly
(Fig. 2b,d). A serum IL-6 level taken 3 weeks after the final
rituximab dose had decreased from a pre-treatment level
of 29.6 pg/mL to 0.9 pg/mL (reference range <6.0 pg/mL).
The patient remains clinically stable and regularly attends
follow-up clinics. There have been no further admissions
characterised by fever and/or hypotension.
Conclusions
Patients with MCD present with heterogenous symptoms
of a systemic inflammatory response with the most com-
mon features being: malaise, fever, night sweats, weight
loss, generalised lymphadenopathy, splenomegaly, oedema
and cytopenias [2, 3, 16]. It is now acknowledged that
cytokine dysregulation, largely driven by IL-6, is respon-
sible for amplifying this systemic response.
Whereas MCD is known to have a higher incidence in
HIV-infected individuals and generally occurs in those
with a CD4 T-cell count <0.35 x 109 cells/L, unlike
Kaposi’s sarcoma there appears to be no correlation be-
tween relapse of MCD and CD4 T-cell count or the use
of ART [17]. In a systematic review of HIV-associated
MCD totalling 68 patients, the median age was 40 years,
90 % of cases occurred in males and 82 % were in
Caucasians [3]. The median time between HIV diagnosis
and MCD diagnosis for patients in the combined ART
era was 33 months and the median CD4 count at diag-
nosis was 0.156 x 109 cells/L [3]. Of 48 patients diag-
nosed in the combined ART era, 68 % were already on
HIV treatment at the time of diagnosis [3]. Indeed, some
data suggests an increase in the incidence of MCD in
the post-ART era, in contrast to Kaposi’s sarcoma [17].
Fig. 2 Histology of core biopsy from supraclavicular lymph node and radiological findings including a diagnostic FDG-positron emission tomography
(PET) scan and comparative abdominal computed tomography before and after rituximab monotherapy. a PET scan performed during Admission #5
demonstrates widespread avid lymphadenopathy prior to the diagnosis of multi-centric Castleman’s disease (MCD). Images (b) and (c) show
splenomegaly on computed tomography (CT) also during Admission #5. Images (d) and (e) were taken following four doses of rituximab
therapy. The spleen has decreased in size from a maximum length of 15.5 cm (superioinferiorly) to 12.9 cm. f Low power showing regressed germinal
centre and expanded interfollicular zones (H&E, x 100). g High power of interfollicular zone showing plasma cell proliferation (H&E, x 400).
h Immunohistochemical staining for HHV-8 shows nuclear expression in isolated cells in the mantle zone (x 200)
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There are no current diagnostic criteria for MCD dis-
ease activity however the presence of fever and a raised
CRP appear important. Furthermore, there are no
evidence-based criteria for diagnosing HIV-associated
MCD. Previous analyses found the most common pre-
senting symptom in HIV-associated MCD was fever
(100 %) with the majority having lymphadenopathy
(95 %), splenomegaly (86 %) and hepatomegaly (62 %)
[3]. The most consistently reported laboratory finding
is of a significantly elevated CRP [5], which was evident
during each of our patients admissions (Fig. 1). Other
reported lab findings include polyclonal hypergammaglo-
bulinemia, hypoalbuminemia, anaemia and pancytopenia
[5]. The French Agence Nationale de Recherche sur le
SIDA 117 CastlemanB group have proposed criteria for
the diagnosis of HIV-associated MCD, which require
fever, CRP >20 mg/L and at least three of the following
clinical features: peripheral lymphadenopathy, spleno-
megaly, oedema, pleural effusion, ascites, cough, nasal
obstruction, xerostomia, rash, central neurologic symp-
toms, jaundice and autoimmune haemolytic anaemia.
Interestingly, our patient does not satisfy the criteria
having only had lymphadenopathy and splenomegaly.
However, the features on histopathology were diagnos-
tic for MCD. Additionally, while our patient displayed a
drop in haemoglobin below the lower limit of normal dur-
ing each admission (Fig. 1), there were no other features
of haemolysis with bilirubin, lactate dehydrogenase
(Table 1), haptoglobin and direct antibody test all within
normal limits. This indicates that there are likely add-
itional mechanisms for anaemia in MCD. Plasma HHV-8
DNA and plasma IL-6 levels may be useful additional
screening tools for MCD, however these have been yet to
be validated in clinical trials [6].
This case highlights the difficulty in making a diagno-
sis of MCD largely due to heterogeneous symptoms and
signs that may wax and wane and/or mimic other condi-
tions such as sepsis. Certainly due to such difficulties it
is likely that there is often a delay between onset of
symptoms and diagnosis, and that the condition is under
diagnosed [18]. Our patient is typical for HIV-associated
MCD in being male, and having a relatively low CD4 T-
cell count, however he is older than the median age of
44 years. Additionally, his HIV diagnosis was longer than
the median of 3 years. There are, however, similarities
between our patient and a previous report by Lederer et
al. [15], who describe a 55 year old man with chronic
HIV infection for 3 years virologically controlled on
ART with a CD4 T-cell count of 0.107 x 109 cells/L. The
previous case also involved multiple presentations to
hospital with fever, (as well as weakness and diarrhoea),
elevated CRP to 228 mg/L and hypotension to 95/
54 mmHg. However, unlike this case the former did not
require ICU admission or ionotropic support.
This is the first report of hypotension and vasodilatory
shock requiring ICU admission and ionotropic support
in the setting of HIV-associated MCD. It is most likely
that the hypotension associated with both this case and
that of Lederer et al. [15] was related to active HIV-
associated MCD. Additionally it is the first report of MCD
mimicking urosepsis. The patient’s major complaint of
urinary frequency at each admission contributed to an
erroneous provisional diagnosis of urinary tract infection.
It is unclear how our patient’s subjective urinary frequency
related to the radiological findings of perinephric strand-
ing and if this could be related to IL-6-mediated inflam-
mation around the urinary tract. There is little published
data on the relationship between IL-6 and the urinary
tract and it will be interesting to discover if urinary fre-
quency is a feature of future cases of MCD.
While a number of therapeutics are used to treat MCD,
none are curative and the goal is to control the disease
and symptoms. Treatment options include the chemother-
apeutic agents cyclophosphamide, doxorubicin, vincristine,
prednisone (CHOP), antiviral agents, corticosteroids and
biologics including the anti-CD20 monoclonal antibody
rituximab, either as monotherapy or in combination with
other agents.
There is no reliable randomised clinical trial data to
guide the treatment of MCD. A recent study from the
USA demonstrates the most common treatments for
MCD were prednisone monotherapy (33 %) and sole ri-
tuximab therapy (19 % [2]). Cohort studies of rituximab
at 375 mg/m2 weekly for 4 weeks has been shown to be
safe and effective in HIV-associated MCD with 20/21
having clinical remission, haematological and serological
normalisation and 70 % having a radiological response
[19]. In the latter cohort study the 2-year survival was
95 % and disease free survival was 79 %. Another study
found a 92 % sustained remission rate [20].
Monoclonal antibodies targeting IL-6 receptor (IL-6R;
tocilizumab) or free IL-6 (siltuximab) have been trialled
with the aim of interrupting the inflammatory signals
from both host and virally produced IL-6. Early studies
found administration of tocilizumab resolved fevers and
fatigue and improved inflammatory markers including
CRP [21]. In a study of 28 HIV-uninfected patients toci-
lizumab was found to decrease lymphadenopathy and
improve inflammatory markers [22], however only two
patients were HHV-8+. Blockade of IL-6 has also shown
some promise in achieving clinical and laboratory nor-
malisation [23]. In a study of 37 patients with MCD 32/
37 (87 %) obtained a clinical benefit response in a least
one measure, however only 1/37 achieved a complete re-
sponse and 11/37 had a partial response [24]. The use of
tocilizumab in HIV-associated MCD is currently limited.
Interestingly in a report of two cases, tocilizumab was
effective at inducing short-term resolution of symptoms
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and elevated CRP, but patients exhibited relapse of MCD
after 15 and 22 weeks prompting second line treatment
with rituximab, which induced clinical remission in both
cases for 1–4 years [25]. There appears to be an emer-
ging consensus that rituximab with or without etoposide
is appropriate first-line therapy for HIV associated MCD
[6]. The mechanism of rituximab’s action here is unclear
as the majority of HHV-8+ plasmablasts lack surface
CD20 (discussed in [18]).
Despite the rarity of HIV-associated MCD and the lack
of consensus guidelines on diagnosis and treatment,
some progress has been made in the management of this
disease. In a study of 86 cases between 1985 and 2006
the median survival was 12 months [3]. However more
recent data from the USA, reported 92 % of subjects
alive at 2 years [2].
Castleman’s disease exists at a fascinating intersection
between tumour biology, viral infection and immuno-
deficiency. This study builds on previous reports to
illustrate the importance of considering the diagnosis of
MCD in patients with chronic HIV infection presenting
in multiple hospital admissions for sepsis-like episodes
associated with fever and hypotension secondary to
vasodilatory shock, especially if no infective agent is
identified or if lymphadenopathy is clinically or radio-
logically evident. Untreated MCD can lead to signifi-
cant morbidity and mortality, however identification
allows for treatment with newer agents such as rituxi-
mab, which is generally well tolerated and can improve
clinical outcome.
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